RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results